Thursday, April 28, 2016

UPDATE 1-AbbVie to buy Stemcentrx to boost cancer drug portfolio

April 28 (Reuters) - AbbVie Inc said it would buy

privately held oncology company Stemcentrx in a deal valued at

$5.8 billion to expand its portfolio of drugs to treat cancer.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)